Experts say continuous manufacturing adoption uneven; Ipsen releasing batch of drug that has been in short supply;

> French drugmaker Ipsen says that in collaboration with the FDA, it is releasing in November an additional batch of Increlex, its rare disease drug, supplies of which were interrupted when its contractor Lonza decided to shut down a plan in the U.S. that the FDA had cited for manufacturing lapses. Release

> In part 2 of its annual report, experts with CPhI say that drugmakers are moving toward continuous processing but that the adoption will be uneven. Release

> CDMO Patheon is reworking its brand with a new logo and a new tagline, "A healthier world delivered." Release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.